Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 18 people, planned
- Started
- 6 Dec 2024
- Expected to end
- May 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- (S)-Nicotine
- (R)- nicotine
- Racemic nicotine
- Record updated
- 14 May 2026
Who can take part
- Age
- 21 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (3)Hide the full registry criteria
Who can take part
- Healthy on the basis of medical history and limited physical examination
- Current regular user of E-Cigarettes (≥ 15 days in the past 30 days)
Who cannot take part
- • Medications; Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs); Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers); Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum); Any stimulant medications (example: Adderall) generally given for ADHD treatment; Pregnancy; Pregnancy (self-reported and urine pregnancy test); Breastfeeding (determined by self-report); Women of childbearing potential must be using an acceptable method of contraception; Inability to read and write in English; A known propylene glycol/vegetable glycerin allergy; Uncomfortable with getting blood drawn
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Nicotine dependence or nicotine vaping
This trial is currently available in United States.
- Zuckerberg San Francisco General Hospital (ZSFG)San Francisco, United StatesContact: Lisa LawrenceTaking people
About the trial
What the trial wants to find out
In a crossover study, experienced electronic cigarette users will vape 3 different forms of nicotine: natural (derived from tobacco), synthetic, or a 50:50 mixture of both natural and synthetic. The investigators will compare nicotine metabolism, cardiovascular effects, patterns of self-administration, and participants' feelings of craving/withdrawal and enjoyment.
The 3 groups in the trial
- S-nicotine (tobacco) as the starting conditionTreatment being tested
Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (S)-nicotine.
Treatment: (S)-Nicotine, (R)- nicotine, and Racemic nicotine
- R-nicotine (synthetic) as the starting conditionTreatment being tested
Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (R)-nicotine.
Treatment: (S)-Nicotine, (R)- nicotine, and Racemic nicotine
- Racemic (50:50 S- and R- nicotine) as the starting conditionTreatment being tested
Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 50% (S)-nicotine and 50% (R)-nicotine.
Treatment: (S)-Nicotine, (R)- nicotine, and Racemic nicotine
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT05962229, who can take part
- Record updated
- 14 May 2026